Skip to main content

Adalimumab (Humira)

Adalimumab is the most used of the biologics for the treatment of

  • Rheumatoid arthritis
  • Psoriatic arthritis
  • Ankylosing spondylitis
  • Crohn's disease
  • Ulcerative colitis

- It is an anti-TNF antibody that counteracts inflammation.
- It is administered through subcutaneous injection every 2 weeks.
- In 2016, its sales in Europe amounted to €2.8 billion.
- A high percentage of patients form ADAs against this drug, between 20-53%.

Labs that test for drug level:

Karolinska University Lab
University of Tours
KU Leuven

Labs that test for ADA titre:

Karolinska Institutet
Karolinska University Lab
KU Leuven
Sheba Medical Centre